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the cut surface of explants. Alternatively, chondrocytes in cul-
tured tissue may acquire sensitivity to this ubiquitous component
of tissue ﬂuid. These possibilities are under investigation.
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Purpose: Decoy receptor 3 (DcR3), a newly identiﬁed member
of the TNF receptor (TNFR) superfamily, is a soluble receptor
binding to the TNF family including Fas-ligand (Fas-L), LIGHT,
and TL1A. DcR3 is mostly expressed in tumor cells and competi-
tively inhibits TNF binding to TNFR. In this study, we investigated
DcR3 expression and analyzed DcR3 function in osteoarthritis
(OA) cartilage.
Methods: Expressions of DcR3 in chondrocytes were measured
by RT-PCR and westernblotting. OA chondrocytes were incu-
bated with DcR3-Fc chimera protein (DcR3-Fc) before induction
of apoptosis. Apoptosis induced by Fas in OA chondrocytes were
detected with TUNEL staining and westernblotting of caspase 8
and poly (ADP-ribose) polymerase (PARP). Proliferation of chon-
drocytes were analysed by WST assay. After incubation with
DcR3-Fc, PD098059 or SB203580. Activation of extracellular-
signal regulated kinase (ERK), P38 mitogen-activated protein
kinase (P38MAPK) and c-jun N-terminal kinase (JNK) in chon-
drocytes were measured by westernblotting.
Results: DcR3 mRNA and protein were expressed in OA chon-
drocytes. RT-PCR and real-time PCR revealed that DcR3 mRNA
was expressed in all the individual samples of OA and normal
chondrocytes (Fig. 1a). Western blotting conﬁrmed that DcR3
protein was expressed in OA and normal chondrocytes (Fig. 1b).
DcR3 protein inhibited Fas-induced apoptosis in chondrocytes.
TUNEL positive apoptotic cells induced by Fas-L in chondrocytes
were signiﬁcantly decreased in a dose dependent manner when
chondrocytes were pre-incubated with DcR3-Fc protein (Fig.
2a). Cleavage of caspases were also signiﬁcantly decreased
(Fig. 2b).
DcR3 stimulates chondrocytes proliferation. Proliferation assay
revealed that the growth rates of chondrocytes were not signif-
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icantly increased by the treatments with 5000 ng/ml of IgG1 in
control medium. However, the growth rates of chondrocytes were
signiﬁcantly increased by the treatments with least 1000 ng/ml of
DcR3-Fc in control medium (Fig. 2c),
DcR3 stimulates the ERK signaling pathway. Western blotting
revealed that ERK signaling was activated by the treatment with
5000 ng/ml of DcR3-Fc for 10 min (Fig. 3) However, Neither P38
MAPK nor JNK signaling was not activated by the treatment with
5000 ng/ml of DcR3-Fc for up to 30 min (Fig. 3).
Suppression of ERK activity decreased chondrocytes prolifera-
tion introduced by DcR3.
Proliferation assay revealed that chondrocytes proliferation were
signiﬁcantly increased by the treatment with 5000 ng/ml of DcR3-
Fc.
chondrocytes proliferation were inhibited by the treatment with
5000 ng/ml of DcR3-Fc and PD098059 (Fig. 4a). Chondro-
cytes proliferation were increased by the treatment with 50µM of
SB203580, and proliferation were more increased by the treat-
ment with SB203580 and DcR3-Fc (Fig. 4a).
Western blotting conﬁrmed that the activation of ERK signaling
was inhibited by the treatment with 5000 ng/ml of DcR3-Fc and
PD 98059 (Fig. 4b).
Conclusions: Our results strongly suggest that DcR3 actually
protects OA chondrocytes from death via Fas-induced apoptosis
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like RA-FLS in our previous study. Furthermore, we demonstrated
that only DcR3-Fc increased chondrocytes proliferation by itself.
Chondrocytes proliferation is increased by activation of ERK.
DcR3-Fc may be a possible therapy for OA.
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ANK EXPRESSION MODULATES BOTH THE
EXTRACELLULAR PYROPHOSPHATECONCENTRATION,
AND THE PHENOTYPE OF HUMAN OSTEOARTHRITIC
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Purpose: Chondrocyte extracellular pyrophosphate (ePPi) plays
a role in the pathology of calcium deposition diseases and,
potentially, primary osteoarthritis. [ePPi] is determined via a
number of mechanisms that regulate its generation and transport.
The purpose of the current work was to determine the effect
on ePPi and cell phenotype, after either knockdown or over
expression of the PPi transporter Ank in primary chondrocytes.
Methods: Human articular chondrocytes were isolated from car-
tilage obtained from consenting donors undergoing joint replace-
ment surgery. Bovine articular chondrocytes were isolated from
cartilage obtained from the metacarpophalangeal joint of adult
bovines. Chondrocytes were isolated using sequential digestion
with pronase and bacterial collagenase. Cell lines stably express-
ing human Ank (native or C-terminal His tag) were created via
transfection of HEK293 cells with human Ank followed by selec-
tion based on antibiotic resistance, Ank expression and PPi elab-
oration. siRNA transfections were carried out using 1.25ul/cm2 of
Dharmafect 4 lipid. Ank was overexpressed in bovine chondro-
cytes via electroporation (Amaxa) using parameters optimized for
chondrocyte expression of exogenous genes. mRNA levels were
determined via Taqman analysis of RNA prepared directly from
either cartilage explants or cell monolayers. ePPi was measured
via the enzymatic procedure of Lust and Seegmiller.
Results: HEK 293 cells engineered for stable expression of
human Ank elaborated a time dependent increase in extraceullu-
lar PPi (ePPi). Human OA chondrocytes accumulated substantial
amounts of ePPi, and expressed three genes (Ank, nucleotide py-
rophosphatase phosphodiesterase/NPP1 and tissue-nonspeciﬁc
alkaline phosphatase/TNAP) that inﬂuence PPi metabolism. Ank
siRNA effectively knocked-down Ank expression (>80%) in hu-
man OA chondrocytes and this was accompanied by > 90% inhi-
bition of [ePPi]. In human OA chondrocytes, siRNA knock-down
of TNAP, NPP1 or Ank mRNA, was achieved either individually
or in combination with each of the other two genes. Knock-down
of Ank or NPP-1, either alone or in any combination with the
other two genes, blocked the accumulation of ePPi. Knock-down
of TNAP alone had no effect on [ePPi]. Overexpression of Ank
in normal bovine chondrocytes via electroporation led to efﬁcient
expression of human Ank and this was accompanied by the
upregulation of genes related to both catabolism (cathepsin K,
MMP-13), and hypertrophy (type X collagen, tissue transglutam-
inase), and the down-regulation of genes related to anabolism
(type II collagen and aggrecan).
Conclusions: Overexpression of Ank in HEK 293 cells leads
to increased accumulation of ePPi, presumably through Ank’s
transmembrane transport of intracellular PPi (iPPi) to the extra-
cellular medium. Consistent with this concept, knock-down of Ank
expression in human OA chondrocytes blocked the accumulation
of ePPi. The mechanism of generation of iPPi for Ank transport is
unclear; however, the inhibition of ePPi by knock-down of either
Ank or NPP1 suggests that NPP1 hydrolysis of ATP to AMP
and PPi may play a role in providing substrate for Ank-mediated
PPi transport. TNAP knock-down had no effect on [ePPi], sug-
gesting that TNAP activity does not play a major role in either
generating ePPi or hydrolyzing ePPi to inorganic phosphate in
human OA chondrocytes. Overexpression of Ank in chondrocytes
drives changes in cell phenotype that are consistent with those
observed in OA i.e. increased expression of catabolic and hy-
pertrophic genes, and decreased expression of anabolic genes.
These data suggest that increased Ank expression or function
may play a role in the progression of degenerative joint diseases.
150
INVESTIGATING WNT1 INDUCIBLE SECRETED PROTEIN
3 IN OSTEOARTHRITIS AND CHONDROCYTE BIOLOGY
N. Baker1, P. Sharpe2, P. Newham2, W. Barker2, G. Cerillo2,
K. Clements2, C. Langham2, M. Smith2, M. Abbott2,
M. Goldring3, J. Gavrilovic1
1University of East Anglia, Norwich, United Kingdom;
2AstraZeneca, Discovery, Alderley Park, United Kingdom; 3Beth
Israel Deaconess Medical Center, New England Baptist Bone
and Joint Institute and Harvard Medical School, Boston, MA
Purpose: Progressive pseudorheumatoid dysplasia (PPRD) is
a rare childhood disease of articular cartilage. Mutations in the
gene encoding WISP-3 (Wnt1 inducible secreted protein 3), a
member of the CCN (Connective Tissue Growth Factor/Cysteine-
Rich 61/Nephroblastoma Over-expressed) family, have been
identiﬁed in several cases of PPRD. Previous work in another
laboratory suggests WISP-3 may regulate expression of type II
collagen and aggrecan in immortalised chondrocytic cell lines.
IGF-1 (Insulin-like growth factor 1) activates different signalling
pathways in chondrocytic cells to encourage proliferation and
differentiation. IGF-1 activity in cartilage depends on its bioavail-
ability and the responsiveness of chondrocytes. WISP-3 has an
IGFBP (Insulin-like growth factor binding protein) domain. There-
fore, WISP-3 may alter chondrocyte activity by modulating IGF-1
availability and signalling.
The aim of the current project is to further examine the role of
WISP-3 in chondrocyte biology and cartilage matrix turnover.
Methods: The expression of WISP-3 mRNA in osteoarthritic and
normal post mortem cartilage was determined by real time PCR.
Expression of WISP-3 protein in osteoarthritic and normal post
mortem cartilage sections was assessed by immunohistochemi-
cal staining.
